NASDAQ
1.61USD
-0.08 (-4.73%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
541.4M
P/E
—
EPS
—
Beta
1.72
52W range
1.45-3.48
Day range
1.53–1.68
Open
1.61
Prev close
1.69
Volume
2.8M
Avg volume
1.1M
Dividend
0.00
IPO
2021-06-30
https://www.zacks.com/stock/news/2972334/prokidney-corp-prok-reports-q2-loss-misses-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2972334 · 8/10/2026-0.80
https://www.zacks.com/stock/news/2922197/prokidney-corp-prok-reports-q1-loss-tops-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2922197 · 5/15/2026-0.40
https://www.globenewswire.com/news-release/2026/03/25/3262552/0/en/ProKidney-Expands-Senior-Leadership-Team-with-Appointment-of-Greg-Madison-as-Chief-Commercial-Officer.html · 3/25/2026+0.40
https://www.defenseworld.net/2026/02/08/best-mid-cap-stocks-to-consider-february-6th.html · 2/8/2026+0.10
https://www.globenewswire.com/news-release/2025/11/10/3185075/0/en/ProKidney-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Regulatory-and-Clinical-Updates.html · 11/10/2025+0.60
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
